SGMS1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sulotroban (SCHEMBL34187)	0.68	11/20
SCHEMBL1062728	0.49	7/20
Trifluoroacetic Acid (SCHEMBL1061423)	0.48	7/20
SCHEMBL1061980	0.50	6/20
SCHEMBL1059807	0.47	6/20
SCHEMBL488883	0.56	5/20
SCHEMBL1721400	0.41	4/20
SCHEMBL1062554	0.40	4/20
SCHEMBL1296190	0.39	4/20
SCHEMBL1369196	0.51	3/20
SCHEMBL450122	0.48	3/20
SCHEMBL1782414	0.46	3/20
SCHEMBL1480481	0.45	3/20
SCHEMBL1478871	0.43	3/20
SCHEMBL1063930	0.42	3/20
SCHEMBL1478284	0.41	3/20
SCHEMBL1312912	0.39	3/20
SCHEMBL1478874	0.39	3/20
SCHEMBL1478047	0.38	3/20
SCHEMBL1720633	0.36	3/20

Clinical trials — most relevant to SGMS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma	PHASE3	RECRUITING
Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	PHASE2	UNKNOWN
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo	PHASE2	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS)	nan	COMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Precision Medicine for Sng/Pain Control	nan	COMPLETED
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.	nan	RECRUITING
Benefits of Eggs in Combination With a Plant-based Diet	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Enpowering Progression Risk of Cerebral Amyloid Angiopathy	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Egg Intake, Metabolic Outcomes and Choline Levels	nan	RECRUITING
Translational Immunodiagnostics in Stroke (TrImS)	nan	RECRUITING
Structural Network on Prostate Cancer in the French Greater West Region	nan	COMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention	nan	UNKNOWN
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children	nan	NOT_YET_RECRUITING
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Androgens and NAFLD Longitudinal Cohort Study	nan	RECRUITING
Rice Ceramide Supplementation and Skin Health	nan	COMPLETED
Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial	nan	COMPLETED
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SGMS1 binder may also engage these)

Protein	Name	Similarity
Q8VCQ6	—	1.000	Q8VCQ6 →
A0AAS4	—	1.000	A0AAS4 →
Q7TSX5	—	1.000	Q7TSX5 →
Q4JM44	—	0.996	Q4JM44 →
Q7T3T4	—	0.995	Q7T3T4 →
Q9D4B1	—	0.995	Q9D4B1 →
SGMS2	Phosphatidylcholine:ceramide cholinephosphotransferase 2	0.992	landscape →
Q4R763	—	0.987	Q4R763 →
Q20735	—	0.984	Q20735 →
Q20696	—	0.981	Q20696 →
Q9JIS8	—	0.981	Q9JIS8 →
P53439	—	0.981	P53439 →
Q9UHW9	—	0.979	Q9UHW9 →
O77761	—	0.978	O77761 →
Q924N4	—	0.977	Q924N4 →
D4AD75	—	0.976	D4AD75 →
Q810K3	—	0.976	Q810K3 →
Q9VPD3	—	0.976	Q9VPD3 →
Q53P98	—	0.976	Q53P98 →
Q61263	—	0.975	Q61263 →
A0A078H868	—	0.975	A0A078H868 →
Q6U841	—	0.974	Q6U841 →
Q63118	—	0.974	Q63118 →
Q9WVK4	—	0.974	Q9WVK4 →
Q500W7	—	0.974	Q500W7 →
F1QF89	—	0.974	F1QF89 →
Q9V576	—	0.974	Q9V576 →
Q99JY8	—	0.974	Q99JY8 →
P56079	—	0.974	P56079 →
Q6RVG2	—	0.974	Q6RVG2 →